These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Metabolic cardio- and reno-protective effects of empagliflozin in a prediabetic rat model. Huttl M; Markova I; Miklankova D; Oliyarnyk O; Trnovska J; Kucera J; Sedlacek R; Haluzik M; Malinska H J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33475091 [TBL] [Abstract][Full Text] [Related]
4. Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. Obata A; Kubota N; Kubota T; Iwamoto M; Sato H; Sakurai Y; Takamoto I; Katsuyama H; Suzuki Y; Fukazawa M; Ikeda S; Iwayama K; Tokuyama K; Ueki K; Kadowaki T Endocrinology; 2016 Mar; 157(3):1029-42. PubMed ID: 26713783 [TBL] [Abstract][Full Text] [Related]
5. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299 [TBL] [Abstract][Full Text] [Related]
6. In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia. Hüttl M; Markova I; Miklankova D; Zapletalova I; Poruba M; Haluzik M; Vaněčkova I; Malinska H Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768942 [TBL] [Abstract][Full Text] [Related]
7. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat. Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346 [TBL] [Abstract][Full Text] [Related]
8. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Kusaka H; Koibuchi N; Hasegawa Y; Ogawa H; Kim-Mitsuyama S Cardiovasc Diabetol; 2016 Nov; 15(1):157. PubMed ID: 27835975 [TBL] [Abstract][Full Text] [Related]
9. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet. Xu L; Nagata N; Chen G; Nagashimada M; Zhuge F; Ni Y; Sakai Y; Kaneko S; Ota T BMJ Open Diabetes Res Care; 2019; 7(1):e000783. PubMed ID: 31749970 [TBL] [Abstract][Full Text] [Related]
10. Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats. Ala M; Khoshdel MRF; Dehpour AR Oxid Med Cell Longev; 2022; 2022():1197061. PubMed ID: 35126806 [TBL] [Abstract][Full Text] [Related]
11. Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice. Huang CC; Chou CA; Chen WY; Yang JL; Lee WC; Chen JB; Lee CT; Li LC Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830289 [TBL] [Abstract][Full Text] [Related]